Incidence of CAAs (acute phase) · people undergoing initial treatment for KD
It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of CAAs (acute phase) compared with prednisolone (very low certainty).
1 finding from 1 review
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in incidence of any adverse effects after treatment initiation (up to 3… compared with prednisolone (low certainty).
1 finding from 1 review
Acute coronary syndrome · people undergoing initial treatment for KD
1 finding from 1 review
Fever clearance time · people undergoing initial treatment for KD
1 finding from 1 review
Need for extra treatment · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of any adverse effects after treatment initiation (from 30… compared with acetylsalicylic acid (ASA) (very low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) (up to 30 days) · people undergoing initial treatment for KD
1 finding from 1 review
Acute coronary syndrome · people undergoing initial treatment for KD
1 finding from 1 review
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
Need for extra treatment · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in need for additional treatment (up to 30 or 60 days) compared with acetylsalicylic acid (ASA) (low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) · people undergoing initial treatment for KD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with different infusion regimens of IVIG (moderate certainty).
1 finding from 1 review
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in incidence of any adverse effects after treatment initiation ( compared with different infusion regimens of IVIG (low certainty).
1 finding from 1 review
Significant disability assessed using Liverpool Outcome Score RR (M‐H, random‐effects analysis, 95% CI) · children with acute encephalitis
It is very uncertain whether intravenous immunoglobulin with or without standard care changes significant disability assessed using Liverpool Outcome Score RR… compared with standard care alone or placebo (very low certainty).
1 finding from 1 review
Serious adverse events Analysis 11.2 · children with acute encephalitis
It is very uncertain whether intravenous immunoglobulin with or without standard care changes ≥ 1 serious adverse event RR (M‐H, random‐effects analysis, 95% CI) compared with standard care alone or placebo (very low certainty).
1 finding from 1 review
Length of hospital stay · children with acute encephalitis
1 finding from 1 review
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found